Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Secarna Pharmaceuticals GmbH & Co. KG First Subject Dosed in Lipigon’s Phase I Clinical Study with Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceutical’s LNAplus(TM) Technology Platform May 31, 2022 From Secarna Pharmaceuticals GmbH & Co. KG Via AccessWire Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb April 12, 2022 From Secarna Pharmaceuticals GmbH & Co. KG Via AccessWire Secarna Pharmaceuticals' Partner Denali Therapeutics Exercises Option for LNAplusTM Antisense Oligonucleotide Development Program in Neurodegeneration February 22, 2022 From Secarna Pharmaceuticals GmbH & Co. KG Via AccessWire Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies November 10, 2021 From Secarna Pharmaceuticals GmbH & Co. KG Via AccessWire Tickers ACHL Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development of Novel ASO Therapeutics in the Field of CNS Diseases October 26, 2021 From Secarna Pharmaceuticals GmbH & Co. KG Via AccessWire Secarna Pharmaceuticals has Initiated a Transnational Scientific Consortium to Identify New Biomarkers for Personalized Cancer Immunotherapy with ASOs October 25, 2021 From Secarna Pharmaceuticals GmbH & Co. KG Via AccessWire Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec Expand Strategic Partnership in the Field of Antisense Drug Discovery September 02, 2021 From Secarna Pharmaceuticals GmbH & Co. KG Via AccessWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.